Novel antibodies against follicular non-Hodgkin's lymphoma
- PMID: 21658621
- DOI: 10.1016/j.beha.2011.03.002
Novel antibodies against follicular non-Hodgkin's lymphoma
Abstract
The anti-CD20 monoclonal antibody rituximab has revolutionized the treatment of patients with follicular B-cell lymphoma. With the combination of chemotherapy and rituximab the overall survival rate has increased with approximately 30%. Unfortunately, there is resistance to rituximab with relapse of the disease in about 60% of the patients during the first five years of treatment and eventually in all patients. To this end, there is a need to develop improved anti-CD20 monoclonal antibodies and antibodies that target other attractive molecules expressed on the follicular lymphoma cell. This review describes the development and clinical achievements so far of next generation anti-CD20 and other antibodies in the treatment of follicular B-cell lymphoma.
Copyright © 2011 Elsevier Ltd. All rights reserved.
Similar articles
-
Molecular engineering to improve antibodies' anti-lymphoma activity.Best Pract Res Clin Haematol. 2011 Jun;24(2):217-29. doi: 10.1016/j.beha.2011.03.004. Epub 2011 May 7. Best Pract Res Clin Haematol. 2011. PMID: 21658620 Review.
-
Responses to rituximab vary among follicular lymphoma B cells of different maturation stages.Scand J Immunol. 2008 Aug;68(2):159-68. doi: 10.1111/j.1365-3083.2008.02129.x. Scand J Immunol. 2008. PMID: 18702746
-
Superior antitumor activity of SAR3419 to rituximab in xenograft models for non-Hodgkin's lymphoma.Clin Cancer Res. 2009 Jun 15;15(12):4038-45. doi: 10.1158/1078-0432.CCR-08-2808. Epub 2009 Jun 9. Clin Cancer Res. 2009. PMID: 19509168
-
The therapeutic use of rituximab in non-Hodgkin's lymphoma.Eur J Haematol Suppl. 2007 Jan;(67):5-14. doi: 10.1111/j.1600-0609.2006.00789.x. Eur J Haematol Suppl. 2007. PMID: 17206982 Review.
-
Cellular and molecular signal transduction pathways modulated by rituximab (rituxan, anti-CD20 mAb) in non-Hodgkin's lymphoma: implications in chemosensitization and therapeutic intervention.Oncogene. 2005 Mar 24;24(13):2121-43. doi: 10.1038/sj.onc.1208349. Oncogene. 2005. PMID: 15789036 Review.
Cited by
-
Highly efficient, in-vivo Fas-mediated apoptosis of B-cell lymphoma by hexameric CTLA4-FasL.J Hematol Oncol. 2014 Sep 17;7:64. doi: 10.1186/s13045-014-0064-6. J Hematol Oncol. 2014. PMID: 25227919 Free PMC article.
-
Immunotherapy for B-cell lymphoma: current status and prospective advances.Front Immunol. 2012 Jan 24;3:3. doi: 10.3389/fimmu.2012.00003. eCollection 2012. Front Immunol. 2012. PMID: 22566889 Free PMC article.
-
Current and future management of follicular lymphoma.Int J Hematol. 2012 Nov;96(5):544-51. doi: 10.1007/s12185-012-1202-y. Epub 2012 Oct 30. Int J Hematol. 2012. PMID: 23108535 Review.
-
Antibody therapies for lymphoma in children.Cochrane Database Syst Rev. 2016 Jan 19;2016(1):CD011181. doi: 10.1002/14651858.CD011181.pub2. Cochrane Database Syst Rev. 2016. PMID: 26784573 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources